SABS 10-Q: SEC filing
SAB Biotherapeutics
Filed with the SEC on · accession 0001193125-26-448600
SABS filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -7.5% by the first close after the filing.
Summary of the filing
SAB Biotherapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, reporting 90,088,831 common shares outstanding as of November 2, 2026.
Key details
How SABS stock reacted
Close before
$3.18
Nov 4, 2026
First close after
-7.55%
$2.94
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SABS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SABS?
Click hereFrequently asked questions
What did SABS file with the SEC on Nov 5, 2026?
SABS filed a 10-Q (SEC filing). SAB Biotherapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, reporting 90,088,831 common shares outstanding as of November 2, 2026.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did SABS stock react to this filing?
SABS closed at $3.18 before the filing and $2.94 on Nov 5, 2026 (-7.55%).
Other SABS SEC filings
Get alerts when SABS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days